生物科技公司Quotient（股票代码：QTNT）近日披露，除前期已公布的交易条款外，公司还有资格获得基于开发进度、监管审批和商业化表现的里程碑付款。若所有阶段性目标均达成，这项合作协议的潜在总价值最高可达22亿美元。该里程碑奖励机制将分阶段触发，具体金额与产品研发进展、监管部门批准时间及市场销售业绩挂钩。此举进一步凸显了合作伙伴对Quotient技术平台商业潜力的认可，也为公司未来现金流提供了多元化支撑。
生物科技公司Quotient（股票代码：QTNT）近日披露，除前期已公布的交易条款外，公司还有资格获得基于开发进度、监管审批和商业化表现的里程碑付款。若所有阶段性目标均达成，这项合作协议的潜在总价值最高可达22亿美元。该里程碑奖励机制将分阶段触发，具体金额与产品研发进展、监管部门批准时间及市场销售业绩挂钩。此举进一步凸显了合作伙伴对Quotient技术平台商业潜力的认可，也为公司未来现金流提供了多元化支撑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.